All Oncology News

Acting ahead of schedule, the FDA has granted an accelerated approval to ibrutinib as a treatment for patients with mantle cell lymphoma who have received at least one prior therapy.

Everolimus provides clinical benefit to patients with papillary metastatic renal cell carcinoma, offering promising overall survival results and a tolerable side-effect profile, investigators found in a study presented during the 2013 European Cancer Congress in Amsterdam.

One oncology practice in Florida seems to have been able to adapt its practice model, taking advantage of economies of scale, and identifying new revenue streams, while still providing quality care and keeping its oncologists satisfied professionally.

A systematic review finds limited evidence of benefit.

Goal is to identify tests and treatments of little to no benefit.

The FDA has approved obinutuzumab plus chlorambucil as a first-line treatment for patients with chronic lymphocytic leukemia, based on clinical trial data demonstrating that the combination more than doubled median PFS over the chemotherapy agent alone.

Marketing and commercial distribution of ponatinib has been temporarily suspended, following an ongoing FDA investigation that revealed an increased frequency of arterial thrombosis and severe narrowing of the blood vessels.

Intervention doubled palliative care consultations; lowered in-hospital mortality and hospital readmission rates.

Hyperfractionated radiotherapy improved overall survival rates compared to standard and accelerated radiotherapy when administered without concomitant chemotherapy in patients with locally advanced head and neck squamous cell carcinoma.

Newest OncLive partner is a renowned translational cancer center that is at the forefront of comprehensive cancer treatment and research into advanced targeted therapies.

Recommendations issued by the NCI and ASCO.

The PD-1 blocking antibody nivolumab continues to demonstrate sustained clinical activity in previously treated patients with advanced non-small cell lung cancer.

The FDA has assigned a priority review designation to ramucirumab as a second-line treatment for patients with advanced gastric cancer.

IBM's computer will be used to identify effective cancer care.

The phase III PREVAIL trial of enzalutamide in chemotherapy-naïve patients with advanced prostate cancer has been stopped early after meeting its co-primary endpoints of overall survival and radiographic progression-free survival

Breast Oncology Director leads effort to honor luminaries who have helped patients survive

The phase III EPIC trial that was exploring ponatinib in untreated patients with chronic myeloid leukemia has been discontinued following a high occurrence of arterial thrombotic events.

In a phase II clinical trial, the BRAF inhibitor vemurafenib demonstrated antitumor activity in patients with BRAFV600E-mutated papillary thyroid cancer who were either TKI treatment naïve or had received prior TKI treatments.

A meta-analysis of nearly 2000 patients has shown that physical activity may substantially reduce the risk of developing esophageal cancer, especially esophageal adenocarcinoma.

The combination of heat, chemotherapeutic drugs and an innovative delivery system based on nanotechnology may significantly improve the treatment of ovarian cancer while reducing side effects from toxic drugs.

An international research team led by scientists from Georgetown Lombardi Comprehensive Cancer Center has discovered a genetic mutation linked to low-risk bladder cancer.

A VEGF level greater than 0.5 ng/mL in bile aspirated from the pancreas was 93% effective at identifying pancreatic cancer in patients with biliary stricture

Additional investment in and collaboration with ADC Therapeutics

Findings from the first large-scale, genome-wide association study of esophageal adenocarcinoma may lead to new screening tools for those at high risk.

Abiraterone acetate significantly delayed the progression of pain and quality of life deterioration in chemotherapy-naive men with metastatic castration-resistant prostate cancer when taken in combination with prednisone.

A phase III study of the PI3K-delta inhibitor idelalisib in combination with rituximab has been stopped early following a positive interim analysis.

A protein receptor for the "good cholesterol," HDL, may help make breast cancer more aggressive and offer a new target for treating the disease.

The FDA has placed a partial hold on the clinical development of the BCR-ABL inhibitor ponatinib, following the high occurrence of arterial thrombosis in patients treated with the drug.

More than 95 Percent of Advanced Prostate Cancer Patients Receive Multiple Radiation Treatments for Pain Control, Despite Evidence Pointing to Equal Benefit from Single Treatments

Access to Doxil has been inconsistent since mid-2011, when the drug's sole manufacturer announced a voluntary shutdown of production to address significant manufacturing and quality concerns.